Mid-Pharma Companies Pulling in Profits through Externalisation Strategies

Research and Markets (http://www.researchandmarkets.com/reports/c42013) has announced the addition of Mid Pharma Sector: In-licensing and Other Externalization Strategies to their offering.

Mid Pharma companies are EU/US based pharmaceutical companies with 2005 annual revenues of <$10bn. An integral component of the Mid Pharma business model is securing access to promising new drugs through in-licensing and acquisition.

Scope of this title:

-- Segmentation of the Mid Pharma market by key attributes including revenue size, therapy area and geographic focus

-- Analysis of how dependent each Mid Pharma company is on externalization to support current portfolios

-- Examination of which types of externalization strategy are most popular in the Mid Pharma peer set

-- Case studies of how domestic players such as Menarini and Almirall are operating as conduits to the highly fragmented local markets of Europe

Highlights of this title:

-- Segmentation of the PharmaVitae Mid Pharma peer set of 22 companies into 5 clusters the Big 6, CNS-focus, CV-focus, small domestic and multi-business unit clusters.

-- Insight into the deep CNS cardiovascular therapeutic axis that runs through Mid Pharma with CNS (Lundbeck, Forest and Shire) and CV-focused (Servier, King, Menarini and Schwarz) players at either end of the spectrum with the Big 6 players located in the middle range, addressing a broad range of therapy areas.

-- Analysis of how the level of externalization dependency varies within Mid Pharma, from highly committed in-licensors such as Forest to internally-sufficient operations such as Servier.

Reasons to order your copy:

-- Understand why the majority of Mid Pharma companies are committed to populating their portfolios by in-licensing and acquisition

-- Identify which companies are appropriate licensing targets on the basis of their fit according to their scale, therapeutic and geographic focus

-- Learn which types of externalization strategy are responsible for the largest influx of product revenues to Mid Pharma

Companies Mentioned

Abbott Laboratories

Akzo Nobel N.V.

AstraZeneca PLC

Boehringer Ingelheim GmbH

Elan Corporation, plc

Forest Laboratories, Inc

GlaxoSmithKline Plc

IMS Health

Ipsen

Johnson & Johnson

Merck KGaA (36)

Novartis AG

Novo Nordisk A/S

Pfizer Inc

Schering AG

Schering-Plough Corporation

Schwarz Pharma AG

Servier

Shire Pharmaceuticals Group plc

Solvay Group

Wyeth

For more information visit http://www.researchandmarkets.com/reports/c42013

Source: Datamonitor